NCT02325310View on ClinicalTrials.gov

Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 4, 2015

Primary Completion Date

May 3, 2016

Study Completion Date

November 1, 2017

Conditions
MeaslesRubellaMumps
Interventions
BIOLOGICAL

Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®

One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.

Trial Locations (1)

75014

Cochin Port Royal Hospital - Centre d'Investigation Clinique Cochin-Pasteur, Paris

All Listed Sponsors
collaborator

Service de Bactériologie-Virologie-Hygiène, CHU Limoge

UNKNOWN

collaborator

GO-CIC network (Réseau Gynéco-Obstetrical des Centres d'Investigation Clinique)

UNKNOWN

collaborator

REIVAC network (Réseau National d'Investigation Clinique en Vaccinologie)

UNKNOWN

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02325310 - Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR | Biotech Hunter | Biotech Hunter